Roohi Ismail-Khan, MD, MSc

Dr. Roohi Ismail-Khan is a medical oncologist specializing in breast cancer in the Center for Women’s Oncology – Breast Program at Moffitt Cancer Center. Dr. Ismail-Khan’s research interests include reducing or eliminating long-term effects of chemotherapy to improve quality of life. Dr. Ismail-Khan’s research interests include reducing or eliminating long-term effects of chemotherapy to improve quality of life. She is also focused on triple negative breast cancer; an aggressive disease that may respond well to chemotherapy, but often recurs and spreads. She serves as principal investigator on multiple investigator and pharmaceutical sponsored clinical trials. She is the co-director of the new Cardio-Oncology program working closely with Dr. Fradley, director of the program. Dr. Ismail-Kahn is also an active teacher/mentor for USF medical students, internal medicine USF residents, and medical oncology fellows.

Philosophy

Dr. Ismail-Khan finds the field of breast medical oncology an exciting one as advances in treatment and the delivery of targeted therapies improve prognosis for everyone, including patients with advanced stage disease.  The knowledge that breast cancer is not just one disease, but many, just as every patient is unique, also sets a new standard in personalized care.  As a mother of four children herself, Dr. Ismail-Khan is aware of the psychosocial needs of women diagnosed with breast cancer, including the consequences of treatment affecting feelings about their femininity and the impact on the family dynamics.

Provider

Roohi Ismail-Khan, MD, MSc

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Breast Oncology

Print Print Physician Bio

Education & Training

BOARD CERTIFICATION:
  • Medical Oncology
  • Internal Medicine
FELLOWSHIP:
  • University of South Florida, Tampa, FL - Medical Oncology
RESIDENCY:
  • University of South Florida, Tampa, FL - Internal Medicine
MEDICAL SCHOOL:
  • St. George's University of Medicine, Grenada, WI - MD
Provider

Roohi Ismail-Khan, MD, MSc

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Breast Oncology

Print Print Physician Bio

Publications

  • Reich RR, Lengacher CA, Alinat CB, Kip KE, Paterson C, Ramesar S, Han HS, Ismail-Khan R, Johnson-Mallard V, Moscoso M, Budhrani-Shani P, Shivers S, Cox CE, Goodman M, Park J. Mindfulness-Based Stress Reduction in Post-treatment Breast Cancer Patients: Immediate and Sustained Effects Across Multiple Symptom Clusters. J Pain Symptom Manag. 2017 Jan;53(1):85-95. Pubmedid: 27720794.
  • Sajjad M, Fradley M, Sun W, Kim J, Zhao X, Pal T, Ismail-Khan R. An Exploratory Study to Determine Whether BRCA1 and BRCA2 Mutation Carriers Have Higher Risk of Cardiac Toxicity. Genes (Basel). 2017 Feb;8(2). Pubmedid: 28157161. Pmcid: PMC5333048.
  • Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ. A phase I study of indoximod in patients with advanced malignancies. Oncotarget. 2016 Apr;7(16):22928-22938. Pubmedid: 27008709. Pmcid: PMC5008412.
  • Rosa M, Han HS, Ismail-Khan R, Allam-Nandyala P, Bui MM. Beta-catenin Expression Patterns in Matched Pre- and Post-Neoadjuvant Chemotherapy-Resistant Breast Cancer. Ann Clin Lab Sci. 2015 Jan;45(1):10-16. Pubmedid: 25696004.
  • Soliman HH, Jackson E, Neuger T, Dees EC, Harvey RD, Han H, Ismail-Khan R, Minton S, Vahanian NN, Link C, Sullivan DM, Antonia S. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget. 2014 Sep;5(18):8136-8146. Pubmedid: 25327557. Pmcid: PMC4226672.
  • Williams M, Eatrides J, Kim J, Talwar H, Esposito N, Szabunio M, Ismail-Khan R, Kiluk J, Lee M, Laronga C, Khakpour N. Comparison of breast magnetic resonance imaging clinical tumor size with pathologic tumor size in patients status post-neoadjuvant chemotherapy. Am J Surg. 2013 Oct;206(4):567-573. Pubmedid: 23809673.
  • Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromata. J Clin Oncol. 2013 Jun;31(17):2128-2135. Pubmedid: 23650416. Pmcid: PMC4881332.
  • Bardhan P, Bui MM, Minton S, Loftus L, Carter WB, Laronga C, Ismail-Khan R. HER2-positive male breast cancer with thyroid cancer: an institutional report and review of literature. Ann Clin Lab Sci. 2012 May;42(2):135-139. Pubmedid: 22585608.
  • Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012 Feb;30(5):533-538. Pubmedid: 22231041. Pmcid: PMC3295555.
  • Donovan KA, Boyington AR, Ismail-Khan R, Wyman JF. Urinary symptoms in breast cancer: a systematic review. Cancer. 2012 Feb;118(3):582-593. Pubmedid: 21751193. Pmcid: PMC3193898.
  • Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Brit J Cancer. 2011 Jun;104(12):1828-1835. Pubmedid: 21559012. Pmcid: PMC3111195.
  • Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control. 2010 Jul;17(3):173-176. Pubmedid: 20664514.
  • Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer. 2008 May;112(9):2021-2029. Pubmedid: 18300255.
  • Simon GR, Ismail-Khan R, Bepler G. Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol. 2007;39(7-8):1318-1328. Pubmedid: 17600754. Pmcid: PMC3167070.
  • Ismail-Khan R, Robinson L, Williams CC J, Garrett C, Bepler G, Simon G. Malignant pleural mesothelioma: a comprehensive review. Cancer Control. 2006 Oct;13(4):255-263. Pubmedid: 17075562.
  • Khan MA, Andrews S, Ismail-Khan R, Munster PN, Brem S, King J, Reintgen DS, Sondak VK, Daud AI. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control. 2006 Jul;13(3):211-217. Pubmedid: 16885917.

Provider

Roohi Ismail-Khan, MD, MSc

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Breast Oncology

Print Print Physician Bio

Participating Trials

CLINICAL TRIAL 17835
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Condition: Breast
Intervention: Not Applicable; Paraplatin (carboplatin); Placebo; Taxol (paclitaxel); Veliparib (ABT-888); carboplatin; paclitaxel
Open

CLINICAL TRIAL 18649
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination with Folate Receptor Alpha Peptides with GM-CSF in Patients with Triple Negative Breast Cancer Defined as Primary Tumor that is Her2-neu Negative and Low (< 10%) ER/PR Nuclear Staining.
Condition: Breast
Intervention: FR alpha peptide vaccine; GM-CSF; Leukine (GM-CSF); cyclophosphamide; cytoxan (cyclophosphamide); sargramostatin (GM-CSF)
Open

CLINICAL TRIAL 18356
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Condition: Breast
Intervention:
Open

CLINICAL TRIAL 18386
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Condition: Breast
Intervention: Not Applicable
Open

CLINICAL TRIAL 18118
Multicenter Study Investigating Utilization of Pharmacokinetic(PK)-Guided Docetaxel in Senior Adult Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy
Condition: Breast
Intervention: Taxotere (docetaxel); cyclophosphamide; cytoxan (cyclophosphamide); docetaxel
Open

CLINICAL TRIAL 18862
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients with LIV-1-Positive Metastatic Breast Cancer
Condition: Breast
Intervention: Herceptin (Trastuzumab); SGN-LIV1A; Trastuzumab; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 18777
Multisite Pilot Phase I HER-2 Pulsed DC Vaccine to Prevent Recurrence for Patients with HER-2 Driven High Risk Invasive Breast Cancer (UPCC 25113)
Condition: Breast
Intervention: HER-2 Pulsed-DC Vaccine
Open

CLINICAL TRIAL 18777
Multisite Pilot Phase I HER-2 Pulsed DC Vaccine to Prevent Recurrence for Patients with HER-2 Driven High Risk Invasive Breast Cancer (UPCC 25113)
Condition: Breast
Intervention: HER-2 Pulsed-DC Vaccine
Open

CLINICAL TRIAL 17268
I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2)
Condition: Breast
Intervention: AMG 386; Adriamycin (doxorubicin); BMN-673 (Talazoparib); CPT-11 (irinotecan); Camptosar (irinotecan); Ganetespib (STA-9090); Ganitumab; Herceptin (Trastuzumab); MK-2206; Not Applicable; PLX3397; Patritumab; Pembrolizumab (Keytruda); Pertuzumab; T-DM1; Talazoparib; Taxol (paclitaxel); Trastuzumab; U3-1287 (Patritumab); cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin; irinotecan; paclitaxel; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 18205
A Study in Patients Treated with MM-398 to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Condition: Breast
Intervention: Ferumoxytol; MM-398
Open

CLINICAL TRIAL 18621
A Phase 1/2 Study of Talimogene laherparepvec in Combination with Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Condition: Breast
Intervention: Adriamycin (doxorubicin); Talimogene laherparepvec 10^6 PFU (Talimogene Laherparepvec); Talimogene laherparepvec 10^8 PFU (Talimogene Laherparepvec); Taxol (paclitaxel); cyclophosphamide; cytoxan (cyclophosphamide); doxorubicin; paclitaxel
Open

CLINICAL TRIAL 18079
Combination Immunotherapy with Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Condition: Breast
Intervention: E75; GM-CSF; Herceptin (Trastuzumab); Leukine (GM-CSF); Placebo; sargramostatin (GM-CSF)
Open

CLINICAL TRIAL 17985
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors
Condition: Multiple
Intervention: INCB024360 (Epacadostat); MEDI4736 (Durvalumab)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).


Provider

Roohi Ismail-Khan, MD, MSc

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Breast Oncology

Print Print Physician Bio

Provider

Roohi Ismail-Khan, MD, MSc

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Breast Oncology

Print Print Physician Bio